Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule

Exclusion Criteria

• •Valvular atrial fibrillation or paroxysmal atrial fibrillation
• •NYHA functional class IV or LVEF \<40%, LA diameter \>55mm;
• •Moderate to severe left ventricular hypertrophy (wall thickness \>1.5cm);
• •Patients with acute coronary syndrome or requiring stent implantation
• •Patients with a history of cardiac surgery within the past 6 months or previous catheter ablation
• •Duration of atrial fibrillation ≥5 years;
• •Hyperthyroidism;
• •Patients with atrial fibrillation and cardiomyopathy;
• •Patients with bradyarrhythmia requiring pacemaker implantation
• •Known bleeding diathesis, presence of left atrial/left atrial appendage thrombus, or severe hemostasis and coagulation dysfunction
• •Severe hepatic or renal insufficiency ALT ≥3 × ULN or eGFR \<45 ml/min/1.73 m²;
• •Patients allergic to the components of the study drug;
• •Patients who are currently participating or have participated in other interventional clinical studies within the past 3 months.
• •Pregnant or lactating women, or those with an expected lifespan of \<12 months;
• •Other vulnerable groups, excluding the elderly/illiterate individuals, including those with mental illnesses, cognitive impairments, critically ill patients, etc
• •Any other reasons deemed by the investigator as unsuitable for the patient's participation in this study